Recruiting OBSERVATIONAL NCT04871035

Immunoadsorption Versus Plasma Exchange for Treatment of Guillain-Barré Syndrome (GBS) (IPET-GBS)

Sponsor: DiaMed GmbH

Conditions GBS

Interventions Immunoadsorption Plasma Exchange

Updated 7 times since 2021 Last updated: Apr 30, 2026 Started: Apr 28, 2021 Primary completion: Sep 1, 2027 Completion: Sep 1, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on GBS, this trial is actively recruiting participants. The trial is conducted by DiaMed GmbH and has accumulated 7 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

May 4, 2026 — Present [daily]

Recruiting
Sep 2024 — May 2026 [monthly]

Recruiting
Jul 2024 — Sep 2024 [monthly]

Recruiting
Jun 2024 — Jul 2024 [monthly]

Recruiting
Jun 2023 — Jun 2024 [monthly]

Recruiting

▶ Show 2 earlier versions

Oct 2021 — Jun 2023 [monthly]

Recruiting
Jun 2021 — Oct 2021 [monthly]

Recruiting

First recorded

Apr 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

This is an observations study evaluating safety and efficacy of immunoadsorption compared to plasma exchange in Guillain-Barré Syndrome.

Contact Information

Sponsor contact:

DiaMed GmbH
University of Ulm

Data source: ClinicalTrials.gov

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Ulm, Germany